Clinical trials
Observational Premature Birth trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 10 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital Tuebingen | 5 |
| Charite University, Berlin, Germany | 3 |
| University Hospital of Cologne | 3 |
| University of Cologne | 3 |
| Global Foundation for the Care of Newborn Infants | 2 |
| Asklepios proresearch | 1 |
| Assaf-Harofeh Medical Center | 1 |
| Goethe University | 1 |
| Hôpital Armand Trousseau | 1 |
| Indiana University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Premature Birth | 28 |
| Ductus Arteriosus, Patent | 2 |
| Acute Kidney Injury | 1 |
| Agnosia | 1 |
| Anxiety Disorders | 1 |
| Bronchopulmonary Dysplasia | 1 |
| Cone-Rod Dystrophies | 1 |
| Edema | 1 |
| Facies | 1 |
| Fetal Growth Retardation | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.